Rigel Pharmaceuticals, Inc. (RIGL) has kicked off 2025 with strong financial results, delivering a profitable first quarter on the back of rising product sales and strategic pipeline investments.
Rigel is a commercial-stage biotech company focused on hematologic disorders and cancer. Its marketed therapies include TAVALISSE, GAVRETO, and REZLIDHIA, targeting conditions such as immune thrombocytopenia, RET-altered cancers, and relapsed/refractory AML, respectively.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.